The same AI systems that can design life-saving drugs can, in theory, design the opposite. Anthropic, OpenAI, and Google DeepMind have decided to get ahead of that problem before it becomes a crisis.
The three dominant AI labs are rolling out a suite of safety measures targeting biological applications of their models, from drug discovery and disease research to pandemic preparedness. The coordinated push includes real-time content classifiers, vetted researcher access programs, and extensive red teaming, all designed to let the good science through while slamming the door on bioweapons research.
A public letter and a line in the sand
In June 2026, the CEOs of all three companies signed a public letter directed at US lawmakers. The message was blunt: synthetic DNA and RNA providers need mandatory screening and recordkeeping requirements, because AI is making it significantly easier to design dangerous biological agents.
Google DeepMind moved first on a concrete program. On July 16, the company announced its bioresilience initiative, which pairs trusted researchers with rapid-deployment drug design engines. DeepMind’s approach leans heavily on its Isomorphic Labs subsidiary, which has been building AI systems specifically for drug discovery. The bioresilience program extends that work into defensive territory, focusing on counteracting biological threats rather than just finding new medicines.
